Central endoscopy reading in inflammatory bowel diseases

Journal of Crohn's and Colitis

Volumn 10, Issue , 2016, Pages S542-S547

  Panés, Julián ^a   Feagan, Brian G ^b   Hussain, Fez ^c   Levesque, Barrett G ^b,d   Travis, Simon P ^e  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c IQVIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); COLITIS, ULCERATIVE; CROHN DISEASE; DIGESTIVE TRACT ENDOSCOPY; HUMAN; OBSERVER VARIATION; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PATIENT ACUITY; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; ELIGIBILITY DETERMINATION; ENDOSCOPY, DIGESTIVE SYSTEM; HUMANS; OBSERVER VARIATION; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ACUITY; TREATMENT OUTCOME;

EID: 85010897865     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv171     Document Type: Article

References (14)

1. Thia K, Faubion WA Jr, Loftus EV Jr, et al. Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis 2011;17:105-11.
2. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
3. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-8.
4. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63:88-95.
5. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763-86.
6. Levesque BG, Sandborn WJ, Ruel J, et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 2015;148:37-51.
7. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535-42.
8. Khanna R, Zou G, D'Haens G, et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut 2015, in press. PMID: 25935574.
9. Gottlieb K, Travis S, Feagan B, et al. Central reading of endoscopy endpoints in inflammatory bowel disease trials. Inflamm Bowel Dis 2015;21:2475-82.
10. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013;145:149-57.
11. Hebuterne X, Lemann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62:201-8.
12. Vermeire S, O'Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: A randomised, controlled, phase 2 trial. Lancet 2014;384:309-18.
13. Travis SP, Schnell D, Feagan BG, et al. The impact of clinical information on the assessment of endoscopic activity: characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis 2015;9:607-16.
14. Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11.